Startups
Norlase
Ballerup, Denmark · Redwood City, California, United States
Norlase ApS is a Danish ophthalmic medical-device company (CVR/VAT35644547) commercializing laser technology developed at the Technical University of Denmark. It develops compact laser photocoagulation systems for retinal disease and glaucoma. Its LEAF, LION, ECHO and LYNX products combine semiconductor-laser technology with portable, fiberless designs, pattern scanning, wireless interfaces and voice control. The company operates in Ballerup, Denmark and Redwood City, California. Its relevance is deep technology, photonics and vision-related medical devices; voice control is a published feature, while an AI drug-discovery or neural-implant platform is not claimed. The live management page publishes eight named leaders and their authentic captioned portraits. Board releases document co-founder Jacob Philipsen becoming chair in February2025, succeeding co-founder David Hardwick, who remained a board member. Maya Barley’s board appointment was announced July2024. These board affiliations are qualified to the latest source dates where a complete current board index is unpublished. Primary sources verify an additional USD4.1million equity raise during2020 through West Hill Capital, USD10.6million SeriesB announced October25,2021, and USD11million financing announced in the body of the May23,2023 release. West Hill organizes investor syndicates; these links do not assert its LLP treasury supplied every dollar. The European Investment Bank project register records a EUR20million venture-debt facility signed December20,2024, announced February27,2025; capacity is distinguished from unknown actual drawdowns. Spring Nordic’s own portfolio verifies an undated investment relationship with no inferred priced round. CORDIS verifies three separate Horizon2020 grant agreements: CoDiS672196, CoDiS734075 and MILAS739714. Their Norlase net contributions are EUR50000, EUR1180012.05 and EUR114780 respectively. CoDiS734075 total project EU contribution EUR1423043.30 includes other beneficiary allocations and is not wholly Norlase cash. Grant agreements, project cost, paid cash, secondary share transactions and cumulative fundraising totals remain distinct. Other older national/programme awards and secondary ownership are retained in the research queue until precise beneficiary, institution and event evidence is established.
Team
 Andrew BerkowitzVice President, Global Strategic Planning |
 Danny NoordegraafChief Technology Officer |
David HardwickBoard Member and Co-founder (last confirmed February2025) |
 Greg FavaVice President, Medical Devices |
 Jacob PhilipsenChairman and Co-founder (appointed February2025) |
 Jan ForstbergVice President, Regulatory Affairs and Quality Assurance |
 Maya BarleyBoard Member (appointment reported July2024) |
 Oliver HvidtCEO and Co-founder |
 Peter IsakssonChief Operating Officer |
 Peter M. W. SkovgaardChief Scientific Officer and Co-founder |
 Taoufiq JellalVice President, Global Distribution |